Breast Cancer Treatment Market Outlook to 2022

Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions.

Table of Contents

Chapter 1 Methodology and Scope

Research Methodology
Segmentation
Research Scope & Assumptions
Market Definition
Chapter 2: Disease Backdrop & Patient Potential

Executive Summary

2.1 Breast Cancer 101

2.2 Etiology

2.3 Pathophysiology

2.4 Disease Burden and Economic Impact

2.5 Healthcare Expenditure (U.S., Top 5 EU and Japan)

2.6 Current Prevalence, Incidence, Risk & Co-Morbidities (U.S., Top 5 EU and Japan)

2.7 Forecast Prevalence, Incidence, Risk & Co-Morbidities (U.S., Top 5 EU and Japan)

Chapter 3: Commercial Insights

Executive Summary

3.1 Market Overview

3.2 Current Market Size

3.3 Total Addressable Market

3.4 Current Treatment Algorithm

3.5 Future Treatment Paradigm

Highlights

Key Insights Addressed: -

Defining market size from 2013 to 2015.

Estimating market growth till 2024 and consequence market forecast.

Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.


Market segments and regions that will drive or lead market growth.

A bird’s-eye view of competitive landscape and the key market players.


Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.


Key Findings: -


Breast cancer is conventionally segmented into three forms, depending on whether the tumor is driven by signaling through the estrogen receptor (ER+), the HER2 receptor (HER2+), or neither (triple negative)

The American Cancer Society estimates that approximately 252,710 women will be diagnosed with breast cancer in the U.S. in 2017, and approximately 40,610 patients will die from the disease

For HER2+ disease, a variety of HER2-receptor targeted agents have been developed that include Roche’s Herceptin, Perjeta, Kadcyla and GSK’s Tykerb,

More recently, Puma’s neratinib produced a statistically significant disease free survival benefit in the extended-adjuvant setting and received FDA approval in July 2017

http://optimainsights.org/reports/breast-cancer-treatment-market-outlook-to-2022

Optima Insights is an innovative research and insights driven enterprise committed to offer actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content holds the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them take better business decisions towards attaining market leadership.

Email Us at: sales@optimainsights.org | Reach Us at: +91 966 6620 365 | +1 424 2554 365 (US)

This release was published on openPR.